Loading the section…

ARQT: financial statements from SEC — TradeAlmanac

ARQT

Arcutis Biotherapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024
Revenue	376M	197M
Cost of revenue	37M	19M
Research and development	77M	76M
Selling, general and administrative	275M	229M
Operating expenses	388M	325M
Operating income	−12M	−128M
Income tax	1M	647,000
Net income	−16M	−140M
Earnings per share	−0.13	−1.16
Earnings per share, diluted	−0.13	−1.16
Weighted average shares	127M	121M
Weighted average shares, diluted	127M	121M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	35M	43M	47M	73M	54M	72M	135M	85M
Receivables	144M	146M	115M

Cash flow

Metric	31/12/2025	31/12/2024
Operating cash flow	−6M	−112M
Depreciation and amortisation	—	640,000
Share-based compensation	40M	42M
Capital expenditure	686,000	143,000
Investing cash flow	−30M	29M
Financing cash flow	7M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator